Subsidies for Genetic Tests

Familial Hypercholesterolemia (FH)

Proband testing (gene panel)

LDLR, PCSK9, APOB

Individuals with low-density lipoprotein cholesterol (LDL-C) ≥ 5.5 mmol/L (≥ 212 mg/dL).

Individuals are eligible for subsidy once per lifetime.

$764

Cascade testing (variant-specific)

LDLR, PCSK9, APOB

First-degree[2] (opens in new tab) biological relatives of an individual who carries a pathogenic / likely pathogenic variant for Familial Hypercholesterolaemia.

Individuals are eligible for subsidy once per variant.

$334

Hereditary Breast Cancer

Proband testing (gene panel)

ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11 or TP53

An individual with personal history of breast cancer who fulfils any one of the following clinical criteria:

 1.         A pathogenic variant identified on tumour genomic testing that has clinical implications if also identified in the germline

2.       Personal history of breast cancer with specific features:

• ≤50 years old

• Triple-negative breast cancer

• Multiple primary breast cancers (synchronous or metachronous)

• Lobular breast cancer with personal or family history of diffuse gastric cancer

• Male breast cancer

3.       Ancestry: Ashkenazi Jewish ancestry

4.       Family history of:

• ≥1 close biological relative with ANY:

  • Breast cancer at age ≤50 years old

  • Male breast cancer

  • Ovarian cancer

  • Pancreatic cancer

  • Prostate cancer with metastatic, or high- or very-high-risk group

• ≥3 diagnoses of breast and/or prostate cancer (any grade) on the same side of the family including the patient with breast cancer

5.       Individuals who otherwise do not meet the criteria 1 to 4 above but have a probability >10% of a BRCA1/2 pathogenic variant based on prior probability models (e.g., Manchester Score, CanRisk)

Individuals are eligible for subsidy once per cancer diagnosis.

$1,000

Individuals with significant family history

(Gene Panel)

ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11 or TP53

Individual with a significant family history of breast cancer, and unknown familial genetic status

For the characterisation of germline gene variants in an unaffected individual who fulfils the following criteria:

 1.         The individual has a first-degree biological relative with breast cancer who is unavailable for genetic testing; and

2.         The individual has a probability ≥10% of a BRCA1/2 pathogenic variant based on prior probability models (e.g. Manchester Score, CanRisk)

Individuals are eligible for subsidy once per lifetime

Cascade testing (variant-specific)

ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11 or TP53

First-degree relatives of an individual who carries a pathogenic or likely pathogenic variant in a breast cancer susceptibility gene.

For the detection of a specific germline pathogenic or likely pathogenic variant previously identified in a first-degree biological relative.

Individuals are eligible for subsidy once per variant.

$550

Hereditary Ovarian Cancer

Proband testing (gene panel)

BRCA1, BRCA2, BRIP1, EPCAM, MLH1, MSH2, PALB2, RAD51C or RAD51D

An individual with a personal history of ovarian cancer who fulfils any one of the following clinical criteria:

 1.         A pathogenic variant identified on tumour genomic testing that has clinical implications if also identified in the germline; or

2.         Personal history of epithelial ovarian cancer (including fallopian tube cancer or peritoneal cancer) at any age; or

3.         Individuals who otherwise do not meet the criteria 1 to 2 above but have a probability >10% of a BRCA1/2 pathogenic variant based on prior probability models (e.g. Manchester Score, CanRisk).

Individuals are eligible for subsidy once per cancer diagnosis.

$1,000

Individuals with significant family history

(Gene Panel)

BRCA1, BRCA2, BRIP1, EPCAM, MLH1, MSH2, PALB2, RAD51C or RAD51D

Individual with a significant family history of ovarian cancer, and unknown familial genetic status

For the characterisation of germline gene variants in an unaffected individual who fulfils the following criteria: 

1. The individual has a first-degree biological relative with ovarian cancer who is unavailable for genetic testing; and

2. The individual has a probability of ≥10% of a BRCA1/2 pathogenic variant based on prior probability models (e.g. Manchester Score, CanRisk)

Individuals are eligible for subsidy once per lifetime.

Cascade testing (variant-specific)

BRCA1, BRCA2, BRIP1, EPCAM, MLH1, MSH2, PALB2, RAD51C or RAD51D

First-degree relatives of an individual who carries a pathogenic or likely pathogenic variant in an ovarian cancer susceptibility gene.

For detection of a specific germline pathogenic or likely pathogenic variant previously identified in a first-degree biological relative.

Individuals are eligible for subsidy once per variant.

$550